24/7 Customer Service (800) 927-7671

Diagnostic blood test shows promise in early detection of Parkinson’s

by • May 1, 2016 • No Comments

Early detection of Parkinson’s may assist doctors decide on treatment options or improve disease management. But frequently folks get a neurological examination after symptoms look, when significant brain cells have may already been destroyed. Now a game-changing blood test is being created to donate doctors a reliable method to detect the disease earlier through clinical biomarkers.

The test is being created at La Trobe University in Melbourne, Australia, to reveal abnormal metabolism of blood cells in folks with Parkinson’s. So far it has been trialed on a total of 38 folks, 29 with Parkinson’s and nine in a control group. Professor of Microbiology Paul Fisher at La Trobe has reported which the tests have proven quite reliable.

The development of the blood test is the culmination of new discoveries on the mechanisms of the disease. Scientists believe which neurodegenerative diseases like Parkinson’s and Alzheimer’s involve malfunction of cell mitochondria, the cells’ energy factories. About 10 years ago, Fisher and his lab team found which symptoms in conditions linked to offensive mitochondria may be caused by an “always on” alarm system in the cells.

The discoquite announced which these diseases were connected to a signalling disorder and not an energy insufficiency, as previously idea. Fisher and his team demonstrated this system and showed which in the case of Parkinson’s, the patient’s cells become hyperactive, major to an increase of the production of toxic oxygen by-products. Over time, these injure significant cells in the brain.

The researchers say which the development of the blood test may allow doctors to reliably detect the abnormal metabolism of blood cells in folks suffering of Parkinson’s, enabling treatment options to be provided much earlier. It may in addition lead to detection tools for other neuro-degenerative disorders, such as Alzheimer’s.

La Trobe has now succeded in $640,000 in funding of the Michael J. Fox Foundation for Parkinson’s Research and its funding partner, Shake It Up Australia Foundation, to extend the study. Upon completion of the future stage in development, the study sample can include a total of 100 subjects, 70 with Parkinson’s and a control group of 30.

Further study of the differences in blood cells of Parkinson’s patients and healthy control groups may outcome in a advantageous belief of the disease’s underlying mechanisms.

The team estimates which the diagnostic blood test may be on the market inside the future five years if extra
funding to speed up its development is secured.

Source: La Trobe

Latest posts

by admin • March 5, 2017